GlassScriptPhysician profile
Paul Berger
NPI 1699921163
$21,468.42
in general payments reported to CMS, 2019-2025
27 companies · $2,868 in 2025
The $2,868 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $308 · 2021: $175 · 2022: $2,293 · 2023: $4,071 · 2024: $12K · 2025: $2,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $4,796 · Food and Beverage: $3,461 · Education: $22.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,303.00 |
| Travel and Lodging | $4,796.19 |
| Food and Beverage | $3,460.67 |
| Education | $22.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $10,606.05 | 2020-2025 | Monarch Platform |
| Medical Device Business Services, INC. | $7,227.25 | 2023-2024 | Monarch Platform |
| Pulmonx Corporation | $1,498.95 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $993.84 | 2022-2024 | Da Vinci Surgical System |
| United Therapeutics Corporation | $140.30 | 2019-2025 | |
| Amgen INC. | $138.38 | 2023-2025 | Tavneos, Tezspire |
| Genzyme Corporation | $103.61 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.52 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $96.00 | 2019-2025 | Airsupra, Breztri |
| Siemens Medical Solutions USA, INC. | $91.32 | 2021 | |
| Mauna Kea Technologies, INC. | $83.85 | 2021 | |
| Inspire Medical Systems, INC. | $83.54 | 2024-2025 | Inspire |
| Grifols USA, LLC | $53.80 | 2024-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $46.37 | 2022-2023 | Nucala |
| Merck Sharp & Dohme LLC | $36.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $26.56 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $24.87 | 2022 | |
| Mylan Specialty L.P. | $22.09 | 2024 | |
| Axsome Therapeutics, INC. | $21.52 | 2024 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $19.99 | 2025 | Uptravi, Opsumit |
| Baxter Healthcare | $19.47 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Harmony Biosciences LLC | $16.85 | 2025 | |
| Advanced Respiratory, INC | $15.29 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.